<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072618</url>
  </required_header>
  <id_info>
    <org_study_id>026B</org_study_id>
    <nct_id>NCT00072618</nct_id>
    <nct_alias>NCT00036010</nct_alias>
  </id_info>
  <brief_title>Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients</brief_title>
  <official_title>A Phase I/II Multi-Center Study of Weekly Taxotere (Docetaxel) in Combination With Aptosyn (Exisulind) in Non-Small Cell Lung Cancer (NSCLC) Patients Who Have Failed a Prior Platinum-Containing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the combination of Taxotere and exisulind is an
      effective and safe treatment for patients with advanced NSCLC who have failed a prior
      platinum-containing regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">August 2003</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>52</enrollment>
  <condition>NSCLC</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exisulind</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histologically documented advanced cancer or advanced platinum-refractory non-small cell
        lung cancer. Platinum refractory defined as progressive disease during a platinum regimen
        or within 6 months following treatment.

        Negative serum pregnancy test, if fertile female. Have not taken sulindac (Clinoril®) on
        regular basis for any indication for one week prior to enrollment and willing to remain off
        of sulindac for the duration of the study.

        &gt; 18 years or of legal age. Male patients, or non-pregnant and non-lactating female
        patients either using adequate birth control (oral contraceptives or Provera), surgically
        sterile or post-menopausal.

        Willingness to remain off chronic NSAIDs (with the exception of ibuprofen, naproxen, or
        aspirin) for duration of the study. Low dose aspirin for cardiovascular prevention is
        acceptable.

        No treatment with any other chemotherapy or radiotherapy within 2 weeks prior to entering
        the study.

        Exclusion Criteria:

        Any condition or any medication which may interfere with the conduct of the study.

        Known hypersensitivity to sulindac (Clinoril®) or taxanes. Use of an investigational
        medication or device within one month of initiating study therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2003</study_first_submitted>
  <study_first_submitted_qc>November 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2003</study_first_posted>
  <last_update_submitted>October 18, 2011</last_update_submitted>
  <last_update_submitted_qc>October 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Sulindac sulfone</mesh_term>
    <mesh_term>Sulindac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

